Puma Biotechnology
PBYI · Nasdaq · United States
Share price · PBYI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PBYI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026-15.6%
- 28 Oct 2026-2.7%
Nothing announced by PBYI that day or the session before.
- 24 Sep 2026+5.8%
Nothing announced by PBYI that day or the session before.
- 7 Aug 2026+9.7%
- 22 Jul 2026-8.3%
Nothing announced by PBYI that day or the session before.
- 7 Jul 2026-3.2%
Nothing announced by PBYI that day or the session before.
- 15 Jun 2026-3.5%
Nothing announced by PBYI that day or the session before.
- 2 Mar 2026+12.6%
Nothing announced by PBYI that day or the session before.
- 27 Feb 2026-25.0%
Share of unusual movement by asset
For each asset, the share of PBYI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 25% |
| Sessions with no dated event | — | 75% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(2 total)
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
October 2027 (1)
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $55M | $18M | $42M+ $67M short-term inv. | —$15M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $57M | $19M | $37M+ $57M short-term inv. | —$1.6M operating cash flow | report ↗ |
| 2026-Q1 | $45M | $20M | $36M+ $65M short-term inv. | $3.8M$15M operating cash flow | report ↗ |
| 2025-Q3 | $54M | $16M | $54M+ $41M short-term inv. | —$9.7M operating cash flow | report ↗ |
| 2025-Q2 | $52M | $15M | $55M+ $41M short-term inv. | —$14M operating cash flow | report ↗ |
| 2025-Q1 | $46M | $14M | $63M+ $30M short-term inv. | —$3.6M operating cash flow | report ↗ |
| 2024-Q3 | $81M | $13M | $67M+ $29M short-term inv. | —$11M operating cash flow | report ↗ |
| 2024-Q2 | $47M | $14M | $67M+ $30M short-term inv. | $4.5M$1.0M operating cash flow | report ↗ |
| 2024-Q1 | $44M | $14M | $77M+ $30M short-term inv. | $4.8M$11M operating cash flow | report ↗ |
| 2023-Q3 | $56M | $11M | $82M+ $3.2M short-term inv. | —$11M operating cash flow | report ↗ |
| 2023-Q2 | $55M | $13M | $60M+ $14M short-term inv. | —$3.3M operating cash flow | report ↗ |
| 2023-Q1 | $53M | $13M | $61M+ $9.8M short-term inv. | —$2.6M operating cash flow | report ↗ |
| 2022-Q3 | $57M | $11M | $78M+ $0 short-term inv. | $0.4M$17M operating cash flow | report ↗ |
| 2022-Q2 | $60M | $12M | $53M+ $8.0M short-term inv. | —-$14M operating cash flow | report ↗ |
| 2022-Q1 | $46M | $15M | $64M+ $10.0M short-term inv. | $3.4M-$27M operating cash flow | report ↗ |
| 2021-Q3 | $46M | $19M | $64M+ $24M short-term inv. | $45M$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $228M | $62M | $30M+ $68M short-term inv. | —$42M operating cash flow | report ↗ |
For fiscal year 2025, Puma Biotechnology reported revenue of $228.37M, down 0.9% YoY from $230.47M, and R&D spend of $62.07M, up 13.0% YoY from $54.94M. Cash and equivalents were $29.64M at year-end; net income/loss and quarterly net burn were not disclosed in the provided figures.
The company continues to commercialize NERLYNX (neratinib) for HER2-positive breast cancer in the U.S. through a direct sales force and outside the U.S. through sub-licensees, with approvals in more than 40 countries. It also holds worldwide rights to alisertib, an Aurora Kinase A inhibitor in-licensed from Takeda, and intends to initially develop it in small cell lung cancer and hormone receptor-positive breast cancer, including biomarker-focused populations such as c-Myc amplification and RB1 loss/mutations.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $230M | $55M | $69M+ $32M short-term inv. | —$39M operating cash flow | report ↗ |
| 2023-FY | $236M | $50M | $85M+ $11M short-term inv. | —$27M operating cash flow | report ↗ |
| 2022-FY | $228M | $52M | $76M+ $4.9M short-term inv. | —-$16M operating cash flow | report ↗ |
| 2021-FY | $253M | $72M | $63M+ $19M short-term inv. | $7.3M$21M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 17 sales ($2.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | MILLER MICHAEL PATRICK · director | Open-market sale | 15,000 | $8.10 | $121K | Form 4 |
| 2026-09-14 | Cesano Alessandra · director | Option exercise | 50,000 | $2.93 | $147K | Form 4 |
| 2026-09-14 | WILSON TROY EDWARD · director | Open-market sale | 5,000 | $9.10 | $46K | Form 4 |
| 2026-09-14 | Cesano Alessandra · director | Open-market sale | 62,150 | $9.12 | $567K | Form 4 |
| 2026-09-14 | Cesano Alessandra · director | Option exercise (derivative) | 50,000 | — | — | Form 4 |
| 2026-07-06 | NOUGUES MAXIMO F · Chief Financial Officer | Open-market sale | 9,386 | $8.26 | $78K | Form 4 |
| 2026-07-06 | HUNT DOUGLAS M · See Remarks | Open-market sale | 8,460 | $8.26 | $70K | Form 4 |
| 2026-07-06 | AUERBACH ALAN H · director, President and CEO, 10% owner | Open-market sale | 44,058 | $8.26 | $364K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 156 reporting institutions held 37.9M shares ($220.8M, 73.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ACORN CAPITAL ADVISORS, LLC | 4,131,299 | $26.4M |
| 2 | BlackRock, Inc. | 3,598,952 | $23.0M |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1,942,413 | $12.4M |
| 4 | AMERICAN CENTURY COMPANIES INC | 1,916,346 | $12.2M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,817,681 | $11.6M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,734,649 | $11.1M |
| 7 | MILLENNIUM MANAGEMENT LLC | 1,477,519 | $9.4M |
| 8 | DIMENSIONAL FUND ADVISORS LP | 1,436,106 | $9.2M |
| 9 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 1,138,169 | $7.3M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,017,342 | $6.5M |
| 11 | STATE STREET CORP | 917,590 | $5.9M |
| 12 | KENNEDY CAPITAL MANAGEMENT LLC | 889,601 | $5.7M |
| 13 | AQR CAPITAL MANAGEMENT LLC | 800,194 | $5.1M |
| 14 | Connor, Clark & Lunn Investment Management Ltd. | 782,798 | $5.0M |
| 15 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 775,341 | $5.0M |